Title : PPM based microecosystem today and tomorrow: Towards PPM secured healthy heart supported by personalized stem cell driven preventive, prophylactic, therapeutic and rehabilitative manipulations of the next step generation
Abstract:
A principally new and upgraded systems approach to subclinical and/or diseased states and wellness resulted in a new trend in the healthcare services, is called as Personalized and Precision Medicine (PPM). But despite breakthroughs in translational research that have led to an increased understanding of PPM-based human disease, the translation of discoveries into therapies for patients has not kept pace with medical need.
Genomics and Genomics editing have raised great expectations concerning the impact on PPM-related customizing the individualized treatment based on the use of genomic products and development of targeted drugs. So, PPM has progressed into fields such as gene therapy and surgical treatment/design. And thus the targeted gene-based therapies today represent an important stake for the clinical community, patients, persons-at-risk and biopharma, in terms of market access, of return on investment and of image among the prescribers.
Meanwhile, most disease, trauma, cancer and regeneration-related pathologies are consequences of cellular damage at differing levels. And the key to the mitigating cell and/or tissue damage repair needs cell therapy which, in turn, is becoming a promising treatment that can be tailored not only to an illness but also to an individual patient and even for a person-at-risk. So, simultaneously, regenerative medicine and cellular therapy use cell-rooted products in order to develop PPM-based treatments being based on different sources of stem cells (SCs) which are being used in targeted therapies whilst providing a personalized approach and could give many advantages as well, including a possibility for SC-based individualized therapy be adjusted according to the patient-specific profile. Some strategic fields for SC applications as part of the micro-ecosystem!
For instance, intracerebral SC therapy has provided promising results for treatment of Parkinson’s disease (PD) but do strongly need within the frame of the proper micro-ecosystem cellular reprogramming, originally using induced pluripotent stem cells (iPSCs) but in combination with genome editing, for identification of the roles essential genes play in specific cellular process, whilst securing the availability of less severe phenotypes compared with patient-specific hiPSCs carrying the same mutations, and thus providing the exclusively important functional implications for PPM and PPM-based treatment.
Human iPSCs have emerged as an effective platform for regenerative therapy, disease modeling, and drug discovery whilst allowing for the production of limitless supply of patient-specific somatic cells that: (a) enable advancement in cardiovascular PPM, and (b) granted the development of protocols to differentiate iPSCs to multiple cardiovascular lineages, as well as to enhance the maturity and functionality of these cells.
